Top

Published in:

01-05-2014 | Translational Research and Biomarkers

High Expression of Glucose Transporter 1 on Primary Lesions of Esophageal Squamous Cell Carcinoma is Associated with Hematogenous Recurrence

Authors: Hiroshi Sawayama, MD, Takatsugu Ishimoto, MD, PhD, Masayuki Watanabe, MD, PhD, Naoya Yoshida, MD, PhD, Yoshifumi Baba, MD, PhD, Hidetaka Sugihara, MD, Daisuke Izumi, MD, Junji Kurashige, MD, PhD, Hideo Baba, MD, PhD

Published in: Annals of Surgical Oncology | Issue 5/2014

Abstract

Purpose

Glucose transporter type 1 (Glut1) plays a crucial role in cancer-specific metabolism to adapt to the rapid growth and tumor microenvironment in diverse malignant tumors. This study examined the clinical, pathological, and prognostic features of Glut1 expression on primary lesions of esophageal squamous cell carcinoma.

Methods

Immunohistochemical staining of Glut1 and CD34 was performed using paraffin-embedded sections of tissues obtained from 145 resectable esophageal squamous cell carcinoma patients without preoperative treatment. Microvessel density was calculated from CD34 staining.

Results

Glut1 positivity was observed in 41 patients (28.2 %) and associated with depth of invasion [odds ratio (OR) 2.984; 95 % confidence interval (CI) 1.208–7.371; P = 0.018] and vascular invasion (OR 2.771; 95 % CI 1.118–6.871; P = 0.028) in multivariate analysis. Glut1 positivity was a significant disadvantage to both relapse-free survival [hazard ratio (HR) 2.021; 95 % CI 1.100–3.712; P = 0.023] and esophageal cancer-specific survival (HR 2.223; 95 % CI 1.121–4.411; P = 0.022) in univariate Cox hazard analysis, but was not independently associated with relapse-free survival or cancer-specific survival in multivariate analysis. The relationship between Glut1 expression and first relapse site was investigated. Glut1 positivity was not associated with lymph node recurrence (HR 1.009; 95 % CI 0.402–2.530; P = 0.985) but was significantly associated with hematogenous recurrence (HR 3.701; 95 % CI 1.655–8.273; P = 0.001) in univariate Cox hazard analysis. Microvessel density was calculated to evaluate angiogenesis, and it was observed that Glut1 positivity was significantly associated with high microvessel density (P < 0.001).

Conclusions

Glut1 expression was associated with hematogenous recurrence. The findings provide evidence of the significance of Glut1 expression as a biomarker.

Available only for authorised users

Pardridge WM, Boado RJ, Farrell CR. Brain-type glucose transporter (GLUT-1) is selectively localized to the blood–brain barrier. Studies with quantitative western blotting and in situ hybridization. J Biol Chem. 1990;265:18035–40.PubMed

Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J. Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res. 1996;56:1164–7.PubMed

Carvalho KC, Cunha IW, Rocha RM, et al. GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker. Clinics. 2011;66:965–72.PubMedCentralPubMedCrossRef

Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res. 2009;15:6479–83.PubMedCentralPubMedCrossRef

Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer. 2008;8:705–13.PubMedCrossRef

Garcia-Cao I, Song MS, Hobbs RM, et al. Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell. 2012;149:49–62.PubMedCentralPubMedCrossRef

Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem. 2001;276:9519–25.PubMedCrossRef

Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381(9864):400–12.PubMedCrossRef

Sohda M, Kato H, Suzuki S, et al. ¹⁸F-FAMT-PET is useful for the diagnosis of lymph node metastasis in operable esophageal squamous cell carcinoma. Ann Surg Oncol. 2010;17:3181–6.PubMedCrossRef

10.

Yasuda T, Higuchi I, Yano M, et al. The impact of ¹⁸F-fluorodeoxyglucose positron emission tomography positive lymph nodes on postoperative recurrence and survival in resectable thoracic esophageal squamous cell carcinoma. Ann Surg Oncol. 2012;19:652–60.PubMedCrossRef

11.

Hiyoshi Y, Watanabe M, Imamura Y, et al. The relationship between the glucose transporter type 1 expression and F-fluorodeoxyglucose uptake in esophageal squamous cell carcinoma. Oncology. 2009;76:286–92.PubMedCrossRef

12.

McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97:1180–4.PubMedCrossRef

13.

Tanigawa N, Matsumura M, Amaya H, et al. Tumor vascularity correlates with the prognosis of patients with esophageal squamous cell carcinoma. Cancer. 1997;79:220–5.PubMedCrossRef

14.

Hironaka S, Hasebe T, Kamijo T, et al. Biopsy specimen microvessel density is a useful prognostic marker in patients with T(2–4)M(0) esophageal cancer treated with chemoradiotherapy. Clin Cancer Res. 2002;8:124–30.PubMed

15.

Kleespies A, Guba M, Jauch KW, Bruns CJ. Vascular endothelial growth factor in esophageal cancer. J Surg Oncol. 2004;87:95–104.PubMedCrossRef

16.

Kato H, Takita J, Miyazaki T, et al. Glut-1 glucose transporter expression in esophageal squamous cell carcinoma is associated with tumor aggressiveness. Anticancer Res. 2002;22:2635–9.PubMed

17.

Tohma T, Okazumi S, Makino H, et al. Overexpression of glucose transporter 1 in esophageal squamous cell carcinomas: a marker for poor prognosis. Dis Esophagus. 2005;18:185–9.PubMedCrossRef

18.

Tang S, Gao L, Bi Q, et al. SDR9C7 promotes lymph node metastases in patients with esophageal squamous cell carcinoma. PloS One. 2013;8:e52184.PubMedCentralPubMedCrossRef

19.

Ito T, Shimada Y, Kan T, et al. Pituitary tumor-transforming 1 increases cell motility and promotes lymph node metastasis in esophageal squamous cell carcinoma. Cancer Res. 2008;68:3214–24.PubMedCentralPubMedCrossRef

20.

Sakai M, Kato H, Sano A, et al. Expression of lysyl oxidase is correlated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma. Ann Surg Oncol. 2009;16:2494–501.PubMedCrossRef

21.

Wouters BG, Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer. 2008;8:851–64.PubMedCrossRef

22.

Bertout JA, Patel SA, Simon MC. The impact of O₂ availability on human cancer. Nat Rev Cancer. 2008;8:967–75.PubMedCentralPubMedCrossRef

23.

Kim JW, Dang CV. Cancer’s molecular sweet tooth and the Warburg effect. Cancer Res. 2006;66:8927–30.PubMedCrossRef

24.

Young CD, Lewis AS, Rudolph MC, et al. Modulation of glucose transporter 1 (GLUT1) expression levels alters mouse mammary tumor cell growth in vitro and in vivo. PloS One. 2011;6:e23205.PubMedCentralPubMedCrossRef

25.

Blancher C, Moore JW, Talks KL, Houlbrook S, Harris AL. Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res. 2000;60:7106–13.PubMed

26.

Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2002;53:1192–202.PubMedCrossRef

27.

Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer. 2001;85:881–90.PubMedCentralPubMedCrossRef

Title: High Expression of Glucose Transporter 1 on Primary Lesions of Esophageal Squamous Cell Carcinoma is Associated with Hematogenous Recurrence
Authors: Hiroshi Sawayama, MD
Takatsugu Ishimoto, MD, PhD
Masayuki Watanabe, MD, PhD
Naoya Yoshida, MD, PhD
Yoshifumi Baba, MD, PhD
Hidetaka Sugihara, MD
Daisuke Izumi, MD
Junji Kurashige, MD, PhD
Hideo Baba, MD, PhD
Publication date: 01-05-2014
Publisher: Springer US
Published in: Annals of Surgical Oncology / Issue 5/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-013-3371-1

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

High Expression of Glucose Transporter 1 on Primary Lesions of Esophageal Squamous Cell Carcinoma is Associated with Hematogenous Recurrence

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2014

Thoracopleuropneumonectomy with Riblike Reconstruction for Recurrent Thoracic Sarcomas

The Role of Sentinel Lymph Node Biopsy in Patients with Merkel Cell Carcinoma: Uncertainty Prevails

Aggressive Locoregional Surgical Therapy for Gastric Peritoneal Carcinomatosis

Lymph Node Metastasis in T4 Maxillary Sinus Squamous Cell Carcinoma: Incidence and Treatment Outcome

Prognostic Factors and Causes of Death in Patients Cured of Esophageal Cancer

A Randomized Prospective Study of Lumpectomy Margin Assessment with Use of MarginProbe in Patients with Nonpalpable Breast Malignancies